icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Daclatasvir Plus Sofosbuvir With or Without Ribavirin for Treatment of Chronic HCV Infection in Patients With Advanced Liver Disease: Results of a European Compassionate Use Programme
 
 
  Reported by Jules Levin
EASL 2016 April14-17 Barcelona
 
Welzel TM,1 Petersen J,2 Herzer K,3 Ferenci P,4 Gschwantler M,5 Cornberg M,6 Ingiliz P,7 Berg T,8 Spengler U,9 Weiland O,10 Van der Valk M,11 Klinker H,12 Rockstroh J,9 Peck-Radosavljevic M,13 Zhou Y,14 Jimenez-Exposito MJ,14 Zeuzem S1 1Universitatsklinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany; 2IFI Institut für Interdisziplinare Medizin, Hamburg, Germany; 3Universitatsklinikum Essen (AoR), Essen, Germany; 4Medizinische Universitat Wien, Vienna, Austria; 5Wilhelminenspital, Vienna, Austria; 6Medizinische Hochschule Hannover, Hannover, Germany; 7Center for Infectiology, Berlin, Germany; 8Universitatsklinikum Leipzig, Leipzig, Germany; 9Universitatsklinikum Bonn, Bonn, Germany; 10Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden; 11Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 12Universitatsklinikum Würzburg, Würzburg, Germany; 13Klinikum Klagenfurt, Klagenfurt, Austria; 14Bristol-Myers Squibb, Princeton, NJ

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

EASL7

EASL8

EASL9

EASL10

EASL11

EASL12

EASL13